Title | Glial Fibrillary Acidic Protein in Serum is Increased in Alzheimer's Disease and Correlates with Cognitive Impairment. |
Publication Type | Journal Article |
Year of Publication | 2019 |
Authors | Oeckl, P, Halbgebauer, S, Anderl-Straub, S, Steinacker, P, Huss, AM, Neugebauer, H, von Arnim, CAF, Diehl-Schmid, J, Grimmer, T, Kornhuber, J, Lewczuk, P, Danek, A, Ludolph, AC, Otto, M |
Corporate Authors | Consortium for Frontotemporal Lobar Degeneration German |
Journal | J Alzheimers Dis |
Volume | 67 |
Issue | 2 |
Pagination | 481-488 |
Date Published | 2019 |
ISSN | 1875-8908 |
Abstract | Reliable blood biomarkers for Alzheimer's disease (AD) are missing. We measured astroglial GFAP in patients with AD (n = 28), frontotemporal dementia (bvFTD, n = 35), Parkinson's disease (n = 11), Lewy body dementias (n = 19), and controls (n = 34). Serum GFAP was increased in AD (p < 0.001) and DLB/PDD (p < 0.01), and cerebrospinal fluid GFAP was increased in all neurodegenerative diseases (p < 0.001). Serum GFAP correlated with the Mini-Mental State Examination score (r= -0.42, p < 0.001) and might be a follow-up marker in clinical trials. Sensitivity and specificity of serum GFAP for AD versus bvFTD was 89% and 79% and might be the first blood biomarker in the differential diagnosis of AD and bvFTD. |
DOI | 10.3233/JAD-180325 |
Alternate Journal | J. Alzheimers Dis. |
PubMed ID | 30594925 |